Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cagrilintide - Novo Nordisk

Next Previous
Drug Profile

Cagrilintide - Novo Nordisk

Alternative Names: AM-833 - Novo Nordisk; AM833; NN 9838; NNC-0174-0833

Latest Information Update: 08 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
  • Mechanism of Action Amylin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Obesity
  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 28 Nov 2025 Novo Nordisk plans a phase III trial in Obesity (In adolescents, In children) in the US, Australia, Austria, Belgium, Bulgaria, China, Colombia, Croatia, Denmark, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, and the United Kingdom (NCT07253285).
  • 06 Nov 2025 Phase-III clinical trials in Obesity (SC) (NCT07220642)
  • 24 Oct 2025 Novo Nordisk plans the phase III RENEW 1 trial for Obesity in USA, Argentina, Australia, Canada, France, Germany, Italy, Norway, Poland and UK (SC, Injection) in November 2025 (NCT07220642)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top